# A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema

> **NCT04654351** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 2 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** TAK-667

## Key facts

- **NCT ID:** NCT04654351
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-15
- **Primary completion:** 2021-07-27
- **Final completion:** 2021-07-27
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04654351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04654351, "A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04654351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*